Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sanofi-Aventis S.A. ADR (SNY)

Sanofi-Aventis S.A. ADR (SNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 109,194,208
  • Shares Outstanding, K 2,439,004
  • Annual Sales, $ 52,854 M
  • Annual Income, $ 8,840 M
  • EBIT $ 11,840 M
  • EBITDA $ 18,264 M
  • 60-Month Beta 0.45
  • Price/Sales 2.20
  • Price/Cash Flow 6.31
  • Price/Book 1.34

Options Overview Details

View History
  • Implied Volatility 32.32% (+0.09%)
  • Historical Volatility 25.90%
  • IV Percentile 90%
  • IV Rank 46.29%
  • IV High 48.01% on 04/08/25
  • IV Low 18.81% on 06/09/25
  • Expected Move (DTE 24) 2.30 (5.10%)
  • Put/Call Vol Ratio 0.29
  • Today's Volume 2,392
  • Volume Avg (30-Day) 1,416
  • Put/Call OI Ratio 1.11
  • Today's Open Interest 50,149
  • Open Int (30-Day) 58,551
  • Expected Range 42.84 to 47.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 1.08
  • Number of Estimates 6
  • High Estimate 1.09
  • Low Estimate 1.05
  • Prior Year 0.94
  • Growth Rate Est. (year over year) +14.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.32 +4.20%
on 03/18/26
48.75 -7.41%
on 02/27/26
-2.17 (-4.59%)
since 02/24/26
3-Month
43.32 +4.20%
on 03/18/26
49.42 -8.66%
on 02/11/26
-3.22 (-6.66%)
since 12/24/25
52-Week
43.32 +4.20%
on 03/18/26
56.93 -20.71%
on 03/25/25
-10.79 (-19.29%)
since 03/24/25

Most Recent Stories

More News
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...

SAN.FP : 77.770 (+1.22%)
REGN : 741.69 (+0.70%)
SNY : 45.14 (+0.83%)
Sanofi announces leadership evolution in Specialty Care Business Unit

CAMBRIDGE, Mass. , Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard,...

SAN : 10.90 (-2.24%)
SNY : 45.14 (+0.83%)
Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

JNJ : 235.27 (-0.06%)
LLY : 903.02 (-0.83%)
ABBV : 205.20 (+0.13%)
GSK : 52.95 (+1.85%)
CSLLY : 24.3550 (-1.87%)
PFE : 26.96 (+0.71%)
SNY : 45.14 (+0.83%)
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX

NEW YORK and NEW ORLEANS , Dec. 30, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC ("KSF") are investigating...

DVAX : 15.50 (unch)
SNY : 45.14 (+0.83%)
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Dynavax Technologies Corporation...

DVAX : 15.50 (unch)
SNY : 45.14 (+0.83%)
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupixent...

SAN.FP : 77.770 (+1.22%)
REGN : 741.69 (+0.70%)
SNY : 45.14 (+0.83%)
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years...

SAN.FP : 77.770 (+1.22%)
REGN : 741.69 (+0.70%)
SNY : 45.14 (+0.83%)
UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Medidata , a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an extension of their...

SAN.FP : 77.770 (+1.22%)
SNY : 45.14 (+0.83%)
Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey

NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medidata , a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and Sanofi today announced an...

SAN.FP : 77.770 (+1.22%)
SNY : 45.14 (+0.83%)
Sanofi’s AlphaMedix Achieves Key Efficacy Endpoints in Phase 2 Study

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update...

SNY : 45.14 (+0.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme,...

See More

Key Turning Points

3rd Resistance Point 46.06
2nd Resistance Point 45.63
1st Resistance Point 45.38
Last Price 45.14
1st Support Level 44.70
2nd Support Level 44.27
3rd Support Level 44.02

See More

52-Week High 56.93
Fibonacci 61.8% 51.73
Fibonacci 50% 50.13
Fibonacci 38.2% 48.52
Last Price 45.14
52-Week Low 43.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.